Bartholin gland adenomyoma

Summary

Bartholin gland adenomyoma (MONDO:0003909) is a disease. A subtype of Bartholin gland benign neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Bartholin gland adenomyoma
Mondo ID	MONDO:0003909
DOID	DOID:6518
NCIT	C40300
UMLS	C1511049
MedGen	307248
Anatomy (UBERON)	UBERON:0000460
Is cancer (heuristic)	no

Also known as: adenomyoma of major vestibular gland · Bartholin gland adenomyoma · major vestibular gland adenomyoma

Disease family

This is a subtype of Bartholin gland benign neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › benign neoplasm › benign reproductive system neoplasm › benign female reproductive system neoplasm › vulvar benign neoplasm › vestibular gland benign neoplasm › Bartholin gland benign neoplasm › Bartholin gland adenomyoma

Related subtypes (1): Bartholin gland adenoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.